- Home
- EM vs MOLN Comparison
EM vs MOLN Comparison
Compare EM & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EM | MOLN |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.7M | 144.0M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EM | MOLN |
|---|---|---|
| Price | $1.20 | $3.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $1.25 | ★ $8.38 |
| AVG Volume (30 Days) | ★ 155.3K | 2.0K |
| Earning Date | 06-02-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.30 | N/A |
| Revenue Next Year | $5.26 | $374.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $3.41 |
| 52 Week High | $1.46 | $5.36 |
Technical Indicators
Market Signals| Indicator | EM | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 66.07 | 35.66 |
| Support Level | $1.16 | $3.52 |
| Resistance Level | $1.42 | $3.97 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 73.68 | 5.09 |
Price Performance
Historical ComparisonAbout EM Smart Share Global Limited
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.